Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass DA. Schaeffer EM, et al. Among authors: adra n. J Natl Compr Canc Netw. 2022 Dec;20(12):1288-1298. doi: 10.6004/jnccn.2022.0063. J Natl Compr Canc Netw. 2022. PMID: 36509074
High-dose chemotherapy for relapsed testicular germ cell tumours.
Chovanec M, Adra N, Abu Zaid M, Abonour R, Einhorn L. Chovanec M, et al. Among authors: adra n. Nat Rev Urol. 2023 Apr;20(4):217-225. doi: 10.1038/s41585-022-00683-1. Epub 2022 Dec 7. Nat Rev Urol. 2023. PMID: 36477219 Review.
Salvage therapy for relapsed testicular cancer.
Adra N, Einhorn LH. Adra N, et al. Oncotarget. 2017 Aug 25;8(41):69200-69201. doi: 10.18632/oncotarget.20573. eCollection 2017 Sep 19. Oncotarget. 2017. PMID: 29050196 Free PMC article. No abstract available.
Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy.
Tachibana I, Alabd A, Whaley RD, McFadden J, Piroozi A, Hassoun R, Kern SQ, King J, Adra N, Rice KR, Foster RS, Einhorn LH, Cary C, Masterson TA. Tachibana I, et al. Among authors: adra n. Urol Oncol. 2023 Sep;41(9):394.e1-394.e6. doi: 10.1016/j.urolonc.2023.06.019. Epub 2023 Aug 4. Urol Oncol. 2023. PMID: 37543446
Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.
Antonelli L, Ardizzone D, Ravi P, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Fizazi K, King JM, Adra N, Douglawi A, Cary C, Sweeney C, Fankhauser CD. Antonelli L, et al. Among authors: adra n. Eur J Cancer. 2023 Mar;182:144-154. doi: 10.1016/j.ejca.2022.12.032. Epub 2023 Jan 20. Eur J Cancer. 2023. PMID: 36787661 Free article.
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer.
Antonelli L, Ardizzone D, Tachibana I, Adra N, Cary C, Hugar L, Sexton WJ, Bagrodia A, Mego M, Daneshmand S, Nicolai N, Nazzani S, Giannatempo P, Franza A, Heidenreich A, Paffenholz P, Saoud R, Eggener S, Ho M, Oswald N, Olson K, Tryakin A, Fedyanin M, Naoun N, Javaud C, Cazzaniga W, Nicol D, Gerdtsson A, Tandstad T, Fizazi K, Fankhauser CD; EAU-YAU Penile and Testis Cancer Working Group. Antonelli L, et al. Among authors: adra n. J Clin Oncol. 2023 Dec 1;41(34):5296-5305. doi: 10.1200/JCO.23.00443. Epub 2023 Sep 1. J Clin Oncol. 2023. PMID: 37656935
110 results